NEW YORK (GenomeWeb News) – The Debiopharm Group said on Thursday it has inked a one-year collaboration deal with Quartz Bio for support of the biopharmaceutical group’s translational projects.

Quartz Bio, a clinical bioinformatics firm spun out by Merck Serono last September, will provide its expertise in computational analyses and biomarker discovery to Debiopharm’s projects, which are anticipated to range from next-generation sequencing and clinical biomarker data analyses.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.